Ascendis Pharma A/S (ASND), based in Copenhagen, Denmark, is a biopharmaceutical company that utilizes its proprietary TransCon technology platform to develop advanced therapeutics for ...

Novo Nordisk (NVO) has been granted an exclusive worldwide license to Ascendis Pharma’s (ASND) TransCon technology platform to develop its proprietary products in metabolic and cardiovascular ...

“We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for ...

Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

TransCon CNP Ascendis proprietary TransCon technology platform. With the TransCon technology and our deep understanding of disease biology, it is possible to create medicine with highly ...

- The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant ...

Also Read: Ascendis Pharma’s Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year The agreement includes provisions requiring certain TransCon technology-based ...

Under deal terms announced Monday, Ascendis, which is also based in Denmark, will conduct early development of the product candidates using its TransCon technology. Novo Nordisk will cover the ...

Ascendis Pharma and Frazier Life Sciences ... atrophy,” Cunningham said in the release. “We believe the TransCon technology platform will be the first to achieve long-acting and effective ...

“Ascendis has leveraged its innovative TransCon technology platform to create a suite of highly differentiated product candidates with best-in-class potential that complement our existing pharma ...